RSV Vaccine Research and Development Technology Roadmap
Priority activities for development, testing, licensure and global use of RSV vaccines, with a specific focus on the medical need for young children in low- and middle-income countries
Overview
Vision - There is a need for high-quality, safe, effective, affordable and accessible RSV vaccines that prevent severe disease and death in infants less than 12 months of age and reduce morbidity in children less than 5 years of age, appropriate for use in LMICs.
Strategic Goals - Develop and license high-quality, safe and effective RSV vaccines that prevent severe disease and death in infants less than 12 months of age and to reduce morbidity in children less than 5 years of age, and to ensure they are available and affordable for global use including in LMICs.
Two priority approaches are identified:
1. Development of vaccines for maternal immunization during pregnancy leading to trans-placental antibody transfer and prevention of severe RSV disease in neonates and young infants.
2. Development of vaccines for paediatric immunization to prevent RSV disease in
infants and young children.
